ITERION THERAPEUTICS
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The companyโs lead product, Tegavivint, is a potent and selective inhibitor of the Wnt/b-catenin signaling pathway, implicated in cell proliferation, differentiation, immune evasion, and stem cell renewal. Tegavivint demonstrates pre-clinical in vivo efficacy in several cancer models including desmoid tumors, acute myeloid leukemia (AML), osteosarcoma, and a range of solid tumor types. The Company is currently enrolling a Phase I clinical study of Tegavivint in patients with desmoid tumors at multiple clinical centers in the United States and Canada. It was founded in 2010 and is headquartered in Houston, Texas.
ITERION THERAPEUTICS
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2010-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.iteriontherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
21.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Wordpress Plugins Nginx PHP Contact Form 7 PHP 7 GoDaddy SSL
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
SOV Therapeutics
SOV Therapeutics is a clinical stage biotechnology company developing oral testosterone replacement therapies for adult men.
Current Employees Featured
Founder
Investors List
GPG Ventures
GPG Ventures investment in Series B - Iterion Therapeutics
Sante Ventures
Sante Ventures investment in Series B - Iterion Therapeutics
Lumira Ventures
Lumira Ventures investment in Series B - Iterion Therapeutics
Viva BioInnovator
Viva BioInnovator investment in Series B - Iterion Therapeutics
GOOSE Capital
GOOSE Capital investment in Series B - Iterion Therapeutics
Cancer Prevention and Research Institute of Texas
Cancer Prevention and Research Institute of Texas investment in Series B - Iterion Therapeutics
Sante Ventures
Sante Ventures investment in Series B - Iterion Therapeutics
AngelMD
AngelMD investment in Series B - Iterion Therapeutics
Sante Ventures
Sante Ventures investment in Series A - Iterion Therapeutics
Official Site Inspections
http://www.iteriontherapeutics.com
- Host name: 201.237.12.198.host.secureserver.net
- IP address: 198.12.237.201
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Iterion Therapeutics"
Our Team - Iterion Therapeutics
Manuel Aivado, MD PhD CEO, Aileron Casey Cunningham, MD Partner, Sante Ventures and CMO, Iterion Therapeutics Paul Weiss, PhD Managing Partner, Venture Investors. Ken Carter, PhD Chairman, Noble Life SciencesSee details»
Our Science - Iterion Therapeutics
Tegavivint (BC2059) has been extensively studied in several in vitro and in vivo models with therapeutic potential in a broad range of tumors.Peer-reviewed published research articles summarizing tegavivintโs binding affinity, potency, โฆSee details»
Iterion Therapeutics - Crunchbase Company Profile & Funding
Iterion Therapeutics is a venture-backed, clinical-stage biotechnology company that develops novel targeted cancer therapeutics. The companyโs lead product, Tegavivint, is a potent and โฆSee details»
Iterion Therapeutics - LinkedIn
Iterion Therapeutics is a clinical stage biopharmaceutical company focused on developing novel cancer therapeutics. The company's lead product, tegavivint, is a highly specific and potent first-in ...See details»
Iterion Therapeutics - Overview, News & Similar companies
Feb 20, 2024 Iterion Therapeutics contact info: Phone number: (832) 721-5208 Website: www.iteriontherapeutics.com What does Iterion Therapeutics do? Founded in 2014, Iterion โฆSee details»
Iterion Therapeutics Inc. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Iterion Therapeutics Inc. of Houston, TX. Get the latest business insights from Dun & Bradstreet.See details»
Iterion Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
Www.iteriontherapeutics.com. Holding Company | 2010 | Texas, United States | 10-50 | www.iteriontherapeutics.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. โฆSee details»
Iterion Therapeutics | VentureRadar
Iterion Therapeutics is a clinical-stage company developing novel therapies for cancer and other diseases. The Companyโs lead product, Tegavivint, is... ... Find ...See details»
Iterion Therapeutics Company Profile 2024: Valuation, Funding ...
Iterion Therapeutics General Information Description. Developer of novel targeted cancer therapeutics designed for the treatment of cancer. The company's beta-catenin modulators are โฆSee details»
Iterion Therapeutics - Company Profile - Tracxn
Nov 1, 2024 Iterion Therapeutics - Developer of therapeutics for the treatment of cancer. Raised a total funding of $25.2M over 6 rounds from 13 investors. Iterion Therapeutics has 329 โฆSee details»
Iterion Therapeutics - Craft
Iterion Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapeutics. It provides Tegavivint, a selective inhibitor of the Wnt/ฮฒ-catenin signaling โฆSee details»
Iterion Therapeutics Secures $17 Million to Advance Development โฆ
Feb 16, 2021 For more information on Iterion, please visit https://iteriontherapeutics.com or follow the Company on Twitter and Linkedin. Tiberend Strategic Advisors, Inc. Ingrid Mezo โฆSee details»
Iterion Therapeutics - VentureRadar
"Iterion Therapeutics is a clinical-stage company developing novel therapies for cancer and other diseases. The Companyโs lead product, Tegavivint, is a potent and selective inhibitor of โฆSee details»
iteriontherapeutics.com Reviews: Is this site a scam or legit?
Organization Domains By Proxy, LLC ... In the context of iteriontherapeutics.com, our investigation continues working to pinpoint the specific category, but we welcome your insights โฆSee details»
Iterion Therapeutics Secures $17 Million to Advance Development โฆ
Feb 16, 2021 Iterion is the recipient of an up to $15.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information on โฆSee details»
Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a ...
Feb 20, 2024 Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like protein 1 (TBL1), a downstream target in the โฆSee details»
Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial ...
Nov 9, 2021 The organization also created Texas Children's Health Plan, the nation's first HMO for children; Texas Children's Pediatrics, the largest pediatric primary care network in the โฆSee details»
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial โฆ
HOUSTON, Oct. 19, 2021 /PRNewswire/ โ Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the โฆSee details»
News Archives - Iterion Therapeutics
HOUSTON, Feb. 20, 2024 /PRNewswire/ โ Iterion Therapeutics, an oncology-focused biopharmaceutical company developing small molecule inhibitors of Transducin beta-like โฆSee details»